Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.

International journal of antimicrobial agents - 1 Nov 2018

Avery Lindsay M, Nicolau David P

Abstract excerpt

Ceftazidime/avibactam plus aztreonam (CZA+ATM) is an emerging option to combat carbapenemase-producing Enterobacteriaceae (CPE) expressing resistance via multiple β-lactamases within Ambler classes A, B, C, and D. The benefit of this combination is apparent when the pathogen-specific resistance genotype is characterized. However, rapid molecular diagnostic systems may be unavailable to allow this precision...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azabicyclo Compounds
Share to beta-Lactamase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to beta-Lactamases

Share to Carbapenem-Resistant Enterobacteriaceae

Share to Ceftazidime

Share to Drug Combinations

Share to Drug Synergism

Share to Enterobacteriaceae Infections

Source

Identifiers

PMID: 30044946
DOI: 10.1016/j.ijantimicag.2018.07.011

Genes

CPE
ATM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.PMID 30044946Read ↗

Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hopeSemantic proximity Read ↗

Aztreonam-avibactam synergy, a validation and comparison of diagnostic toolsSemantic proximity Read ↗

Evaluation of two gradient diffusion tests to determine susceptibility to aztreonam and ceftazidime–avibactam in combinationSemantic proximity Read ↗

Comparison of testing methods assessing the in vitro efficacy of the combination of aztreonam with avibactam on multidrug-resistant Gram-negative bacilliSemantic proximity Read ↗

Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical LaboratorySemantic proximity Read ↗

Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015–16Semantic proximity Read ↗

Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative BacteriaSemantic proximity Read ↗

Aztreonam-avibactam: an option against carbapenem-resistant Enterobacterales with emerging resistanceSemantic proximity Read ↗

Comparative Evaluation of Phenotypic Methods for Testing Ceftazidime-Avibactam and Aztreonam Synergy in Carbapenem-Resistant Enterobacterales from a Tertiary Care Center in Eastern IndiaSemantic proximity Read ↗

Analysis of a simple disk diffusion method to evaluate Ceftazidime-avibactam/Aztreonam combination synergism against NDM clinical isolates.Semantic proximity Read ↗

Exploring Aztreonam in Combination with Ceftazidime-Avibactam or Meropenem-Vaborbactam as Potential Treatments for Metallo- and Serine-β-Lactamase-Producing EnterobacteriaceaeSemantic proximity Read ↗

Comparative Evaluation of Commercial Gradient Diffusion and Disk Diffusion Tests for Aztreonam-Avibactam Susceptibility TestingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.